Guidelines for managing cardiovascular risk: An evolving area

Current Opinion in HIV and AIDS

Volumn 3, Issue 3, 2008, Pages 205-206

  Currier, Judith S ^a,c   Lundgren, Jens D ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cardiovascular; Guidelines; HIV; Risk

Indexed keywords

ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT;

CARDIOVASCULAR RISK; DYSLIPIDEMIA; HEALTH CARE PERSONNEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL INFORMATION; METABOLIC DISORDER; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK MANAGEMENT;

EID: 42049089527     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3282fc75fe     Document Type: Review

References (4)

1. Dube MP, Sprecher D, Henry WK, et al. Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group. Clin Infect Dis 2000; 31:1216-1224.
2. Dube MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003; 37:613-627.
3. Schambelan M, Benson C, Carr A, Currier J, et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society - USA Panel. JAIDS 2002; 31:257-275.
4. Lundgren JD, Battegay M, Behrens G, et al. European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med 2008; 9:72-81.